
News|Articles|January 1, 2004
As post-tamoxifen therapy, letrozole cuts breast cancer recurrence 43%
Letrozole therapy, in follow-up to 5 years of tamoxifen treatment, significantly improves disease-free survival compared to placebo, according to a study published in The New England Journal of Medicine.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Jascayd gets second FDA approval, this time for progressive pulmonary fibrosis
2
2025 FDA added indications to dermatologic medications
3
What NCCN’s next CMO sees ahead for cancer guidelines, access and innovation
4
5 developments in the treatment of prurgio nodularis in 2025
5




















































